Pre-order Now — Available: November 1, 2016

• Series Overview
• Program Content
• Faculty
• Target Audience and Program Goals
• CPE Credit
• BCACP Specialty Recertification Credit
• Technical Requirements
• Fees

From Theory to Practice: Clinical Reasoning Series in Ambulatory Care Pharmacy is one component of the professional development program developed by ACCP and approved by the Board of Pharmacy Specialties (BPS) for the recertification of the Board Certified Ambulatory Care Pharmacist (BCACP).

This educational series explores cutting-edge, contemporary therapeutic topics, and demonstrates scientifically sound clinical reasoning and decision-making. It employs learning activities designed to advance the participants’ skills and abilities to critically evaluate the scientific evidence and to effectively incorporate into daily practice significant findings that lead to effective and safe patient care.

“Hepatitis C: The Newest Strategies for Management and Treatment” will provide an in-depth analysis of the current evidence on the use of various agents approved for the management of hepatitis C and discuss the implications for pharmacist patient care services.

“Hepatitis C: The Newest Strategies for Management and Treatment” covers the following content:

• Background of Hepatitis C Virus (HCV)
• Management of HCV in Treatment Naïve and Interferon-Experienced Individuals
• Retreatment and Resistance
• Treating HCV in “Special Populations”
• Role of the Pharmacist in HCV Treatments
• Challenges with HCV Treatment
• The Future of HCV Treatment

	Paulina Deming, Pharm.D., PhC Clinical Associate Professor: Pharmacy Practice & Administrative Sciences College of Pharmacy University of New Mexico Albuquerque, New Mexico
	Michelle T. Martin, Pharm.D., BCPS, BCACP Clinical Pharmacist and Assistant Professor University of Illinois at Chicago Chicago, Illinois
	Kelsey M. Rife, Pharm.D., BCACP Clinical Pharmacy Specialist Louis Stokes VA Medical Center Cleveland, Ohio

Clinical Pharmacists and BCACPs providing care to patients with Hepatitis C.

At the conclusion of the program, the participant should be able to:

1. Discuss direct acting antiviral agents for the treatment of Hepatitis C Virus (HCV).
2. Identify challenges associated with HCV treatment.
3. Apply national guidelines to recommend patient-specific HCV treatment plans.
4. Outline opportunities to advance pharmacist involvement in the management of HCV treatment.

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This is an application-based activity; Activity Number: 0217-0000-16-111-H01-P.

To earn continuing pharmacy education (CPE) credit and to receive your continuing pharmacy education statement of credit for this activity, participants must successfully complete a Web-based posttest by October 23, 2019. Partial credit is not available for this activity.

To be eligible for 6.0 CPE hours of recertification credit, BCACPs must successfully complete a Web-based posttest by November 30, 2016. Partial credit is not available for this activity.

ACCP, as the official provider approved by BPS, will record and report recertification credit earned for this activity directly to BPS.

Requires an Internet browser and Adobe Reader.